Venturi Wealth Management LLC Acquires 133 Shares of Insulet Co. (NASDAQ:PODD)

Venturi Wealth Management LLC boosted its holdings in shares of Insulet Co. (NASDAQ:PODD) by 633.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 154 shares of the medical instruments supplier’s stock after purchasing an additional 133 shares during the period. Venturi Wealth Management LLC’s holdings in Insulet were worth $36,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Sei Investments Co. raised its holdings in shares of Insulet by 16.2% in the first quarter. Sei Investments Co. now owns 11,782 shares of the medical instruments supplier’s stock valued at $2,019,000 after buying an additional 1,639 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its position in shares of Insulet by 3.8% during the first quarter. State Board of Administration of Florida Retirement System now owns 78,435 shares of the medical instruments supplier’s stock worth $13,444,000 after purchasing an additional 2,847 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Insulet by 22.3% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 78,391 shares of the medical instruments supplier’s stock valued at $13,436,000 after purchasing an additional 14,289 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp grew its stake in shares of Insulet by 246.2% during the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 135,547 shares of the medical instruments supplier’s stock valued at $23,168,000 after purchasing an additional 96,390 shares during the last quarter. Finally, Intech Investment Management LLC increased its holdings in shares of Insulet by 113.8% in the first quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier’s stock valued at $1,140,000 after purchasing an additional 3,539 shares in the last quarter.

Insulet Trading Down 0.4 %

Shares of NASDAQ PODD opened at $260.12 on Friday. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $279.40. The stock has a market cap of $18.25 billion, a price-to-earnings ratio of 44.54, a P/E/G ratio of 4.11 and a beta of 1.22. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The company’s fifty day moving average is $237.77 and its 200-day moving average is $207.47.

Analyst Upgrades and Downgrades

PODD has been the topic of a number of recent research reports. Raymond James increased their price objective on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. BTIG Research raised their price target on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a report on Friday, November 8th. Canaccord Genuity Group boosted their price objective on Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. UBS Group raised their target price on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Finally, Citigroup boosted their price target on shares of Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $253.27.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.